Eisai Expands Alzheimer’s Portfolio with 50+ AAIC Presentations — Eisai Inc.

Event summary

Eisai will present over 50 abstracts on its Alzheimer’s disease portfolio at AAIC 2026, including data on lecanemab and etalanetug.
Key sessions include real-world evidence from the LEADER study on lecanemab three years post-approval and findings on subcutaneous administration.
Phase 3 AHEAD 3-45 trial updates will highlight progress in preclinical Alzheimer’s disease.
Eisai will host a symposium on early intervention in Alzheimer’s disease.

The big picture

Eisai’s extensive AAIC 2026 presence underscores its leadership in Alzheimer’s research, particularly with lecanemab and etalanetug. The focus on real-world evidence and subcutaneous administration highlights the company’s strategic shift toward patient-centric treatment options. As competitors race to develop effective therapies, Eisai’s data-driven approach could solidify its position in the rapidly evolving neuroscience sector.

What we're watching

Real-World Evidence: How the LEADER study’s findings on lecanemab’s real-world use will influence regulatory and clinical adoption.
Subcutaneous Administration: The impact of subcutaneous lecanemab formulation on patient compliance and treatment accessibility.
Tau Pathology Research: Whether etalanetug’s Phase 2 trial data will validate its potential as a disease-modifying therapy for Alzheimer’s.